Acquired drug resistance conferred by a KRAS gene mutation following the administration of cetuximab: a case report

[1]  S. Matsusaka,et al.  Acquired drug resistance conferred by a KRAS gene mutation following the administration of cetuximab: a case report , 2013, BMC Research Notes.

[2]  Jie-tao Ma,et al.  Concordant KRAS Mutations in Primary and Metastatic Colorectal Cancer Tissue Specimens: A Meta-Analysis and Systematic Review , 2012, Cancer investigation.

[3]  Enzo Medico,et al.  Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer , 2012, Nature.

[4]  Johannes G. Reiter,et al.  The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers , 2012, Nature.

[5]  P. Jänne,et al.  The road to resistance: EGFR mutation and cetuximab , 2012, Nature Medicine.

[6]  F. Bosch,et al.  Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer , 2012, Nature Medicine.

[7]  Yoko Yamamoto,et al.  Heterogeneity of KRAS Status May Explain the Subset of Discordant KRAS Status Between Primary and Metastatic Colorectal Cancer , 2011, Diseases of the colon and rectum.

[8]  Zhongqi Li,et al.  Heterogeneity in primary colorectal cancer and its corresponding metastases: a potential reason of EGFR-targeted therapy failure? , 2011, Hepato-gastroenterology.

[9]  I. Nagtegaal,et al.  KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients , 2011, British Journal of Cancer.

[10]  F. Lévi,et al.  Acquired KRAS mutations during progression of colorectal cancer metastases: possible implications for therapy and prognosis , 2010, Cancer Chemotherapy and Pharmacology.

[11]  G. Tortora,et al.  EGFR antagonists in cancer treatment. , 2008, The New England journal of medicine.

[12]  Y. Nakamura,et al.  Genetic alterations during colorectal-tumor development. , 1988, The New England journal of medicine.